Back to search
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 trials you may qualify forThis is a first-in-human, open-label, single ascending dose study of TTX-381 for the treatment of ocular manifestations of CLN2 (Batten disease).
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, i…
This is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy of intravitreal administration of cerliponase alfa.
The purpose of this study is to gather information on the possible symptoms that patients with atypical neuronal ceroid lipofuscinosis type 2 (also known as aTP…
This is a multicenter, observational study for patients with a confirmed diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as TPP1 d…